EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 183 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 1.51 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3 | -100.0% | 230 | -83.7% | 0.00% | – |
| Q3 2020 | $59,000 | -66.9% | 1,410 | -62.2% | 0.00% | – |
| Q2 2020 | $178,000 | -82.6% | 3,729 | -83.2% | 0.00% | -100.0% |
| Q1 2020 | $1,023,000 | +8.8% | 22,257 | -4.6% | 0.00% | -33.3% |
| Q4 2018 | $940,000 | +473.2% | 23,341 | +882.8% | 0.00% | +200.0% |
| Q3 2018 | $164,000 | +33.3% | 2,375 | +1.1% | 0.00% | -80.0% |
| Q1 2018 | $123,000 | -60.5% | 2,348 | -59.7% | 0.01% | -61.5% |
| Q4 2017 | $311,000 | +95.6% | 5,830 | +117.5% | 0.01% | +116.7% |
| Q3 2017 | $159,000 | +200.0% | 2,681 | +299.0% | 0.01% | +100.0% |
| Q4 2016 | $53,000 | -44.2% | 672 | -71.4% | 0.00% | -62.5% |
| Q1 2016 | $95,000 | -81.3% | 2,351 | -59.0% | 0.01% | -80.0% |
| Q4 2015 | $508,000 | +39.9% | 5,737 | +27.6% | 0.04% | +33.3% |
| Q2 2015 | $363,000 | – | 4,495 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JW Asset Management, LLC | 475,755 | $25,068,000 | 24.71% |
| Hudson Executive Capital LP | 971,000 | $51,162,000 | 15.09% |
| Park West Asset Management LLC | 1,051,274 | $55,392,000 | 2.47% |
| U S GLOBAL INVESTORS INC | 19,200 | $1,012,000 | 0.62% |
| Capital Impact Advisors, LLC | 26,317 | $1,387,000 | 0.57% |
| CLARK ESTATES INC/NY | 56,278 | $2,965,000 | 0.47% |
| IRIDIAN ASSET MANAGEMENT LLC/CT | 873,131 | $46,005,000 | 0.41% |
| ProQuest Associates IV LLC | 6,777 | $357,000 | 0.41% |
| Granite Investment Partners, LLC | 114,207 | $6,017,000 | 0.40% |
| GLOBEFLEX CAPITAL L P | 30,900 | $1,628,000 | 0.34% |